This clinical trial is for adult participants who have a diagnosis of immune-mediated thrombotic thrombocytopenic purpura (iTTP).
   
The purpose of this study is to find out if an investigational study drug called TAK-755 is effective in treating iTTP with and without the current standard-of-care (SoC) treatment, which is daily plasma exchange (PEX). The purpose is also to find out how safe TAK-755 is, what are the side effects that might be related to it, and how often do they occur.
   

This study is being done to identify if there is a safe, tolerable, and effective schedule of pomalidomide treatment when it is given in combination after induction therapy with daunorubicin and cytarabine liposome for acute myeloid leukemia (AML). Additionally, the study will evaluate if the combination of pomalidomide and daunorubicin and cytarabine liposome induction therapy is more effective in controlling AML than induction therapy with daunorubicin and cytarabine liposome alone.
   

This study is being done to evaluate if adding the drug ipatasertib to the usual approach is able to safely lower the chance of head and neck squamous cell cancer growing or spreading. This study aims to determine if this approach is better or worse than the usual approach.

The usual approach consists of treatment with immunotherapy using pembrolizumab. Pembrolizumab is approved by the U.S. Food and Drug Administration (FDA) and is administered through a vein in the arm.

This study is evaluating the experimental drug selgantolimod (SLGN) for patients with Chronic Hepatitis B (CHB) to try to prevent progression and reverse disease. 

Experimental means that SLGN has not yet been approved by the U.S. Food and Drug Administration (FDA). 

The purpose of this research study is to evaluate whether the 3 experimental study drugs being tested, 3BN117-LS, 10-1074-LS and N-803, are safe and tolerable for participants with HIV. Experimental means that these drugs have not yet been approved by the U.S. Food and Drug Administration (FDA). This study will also look at how well HIV is controlled after stopping antiretroviral therapy (ART).

The purpose of this study is to see if the drug tecovirimat helps people with mpox (formally known as monkeypox) heal faster. The study will also help us understand more about how human mpox causes disease and how the body fights off infection. 
   
Tecovirimat is approved by the U.S. Food and Drug Administration (FDA) for the treatment of smallpox and has been given safely to some people with mpox in the recent outbreak. It is considered investigational in this study as it has not yet been approved to treat mpox.
   

This study ia evaluating the safety and efficacy of the study drug seladelpar in people with Primary Biliary Cholangitis (PBC) and abnormal liver function. This will be done by looking at how the study drug seladelpar affects PBC and observing changes in the laboratory tests that are used to monitor the severity of PBC and its prognosis.

This study is being done to find better ways to diagnose, treat and prevent cancers in children, adolescents, and young adults. To do this, we need to learn more about cancers that happen to these groups. As most cancers that children get are rare, we can best learn by combining information from as many children with cancer as possible.

This study aims to improve outcomes for patients with NCI High Risk B-Cell Acute Lymphoblastic Leukemia (B-ALL) and patients with NCI Standard Risk B-ALL with high risk features. High risk features are when the leukemia has spread to the spinal fluid or testes, or one received steroid treatment before being diagnosed with leukemia.
   

This clinical trial is for men and women with newly diagnosed or relapsed/refractory acute myeloid leukemia.

The purpose of this study is to determine a safe dose of an investigational new drug (ziftomenib) in combination with other study drugs i.e., venetoclax and azacitidine or cytarabine plus daunorubicin. This will include an evaluation of side effects associated with ziftomenib in combination with the other study drugs and also aims to determine how ziftomenib works in combination with the other study drugs.